Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05313802 Completed - Healthy Clinical Trials

A Study of LY3502970 in Healthy Overweight and Obese Participants

Start date: May 26, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

NCT ID: NCT05313568 Active, not recruiting - Healthy Clinical Trials

Self Stretching, Plantar Self Massage and Manual Stimulation on Balance and Reaction Time

Start date: June 28, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the instantaneous effects of self-stretching, plantar self-massage and manual stimulation on balance and reaction time in healthy individuals. 102 individuals meeting the inclusion criteria will be included in the study. Individuals will be randomly divided into 3 groups: static stretching group (n=34), self-massage group (n=34) and manual stimulation group (n=34). Static stretching will be applied to all individuals (n=102). In addition to static stretching, self-massage will be applied to individuals in the self-massage group (n=34). Individuals in the manual stimulation group (n=34) will receive manual stimulation in addition to static stretching. Individuals will be evaluated in terms of static balance, dynamic balance, reaction time and foot functionality before and immediately after the applications.

NCT ID: NCT05309304 Completed - Healthy Clinical Trials

Cefazolin PK Study 3g vs 2g

Start date: February 14, 2022
Phase: Phase 1
Study type: Interventional

Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.

NCT ID: NCT05308940 Completed - Healthy Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects

Start date: January 10, 2022
Phase: Phase 1
Study type: Interventional

It was a randomized, double-blind, placebo-controlled combined single ascending dose (SAD) and multiple ascending dose (MAD) study, evaluating the safety, tolerability and pharmacokinetics of TB001 after single and multiple subcutaneous injections in healthy subjects.

NCT ID: NCT05308745 Completed - Healthy Clinical Trials

Effects of Yakult Ingestion in Residents and Staffs at Indonesian Elderly Houses

Start date: October 4, 2018
Phase: N/A
Study type: Interventional

A study to investigate the effect of Yakult® containing L. casei Shirota on the intestinal microbiota, intestinal environment, and stool frequency in healthy adult and elderly subjects in Indonesia. The clinical phase of this study was conducted for 26 weeks in three different elderly houses. The subjects were grouped into two categories: probiotic and placebo group, according whether the subjects consumed product or placebo samples. Fecal sampling were taken three times during the study.

NCT ID: NCT05308433 Completed - Healthy Clinical Trials

Cybersickness imAgiNg Olfactory Evocation

CANOE
Start date: April 13, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to, using fMRI, compare brain activations during olfactory imagery induced by different visual supports (words, pictures, colors and colored arrangements) in healthy subjects. This will allow us to choose the best olfactory imagery facilitator and to assess its effect on cybersickness.

NCT ID: NCT05307978 Completed - Healthy Clinical Trials

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Start date: April 12, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1910 subcutaneous (SC) and SAD of ALXN1910 intravenous (IV).

NCT ID: NCT05303961 Completed - Healthy Clinical Trials

Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Start date: June 7, 2016
Phase: Phase 1
Study type: Interventional

This study consists of Part 1 followed Part 2. Part 1 The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of a single oral dose of SA001 and active comparator(Rebamipide) in healthy male volunteers. Part 2 The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of multiple oral dose of SA001 in healthy male volunteers.

NCT ID: NCT05303324 Completed - Healthy Clinical Trials

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

Start date: July 4, 2019
Phase: Phase 1
Study type: Interventional

To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).

NCT ID: NCT05303077 Completed - Healthy Clinical Trials

Study of the Effects of a New Infant Formula Supplemented With a Probiotic Over the Corporal Composition of Infants

Start date: February 11, 2019
Phase: N/A
Study type: Interventional

This is a multicentric, randomized, blinded, controlled trial to study the effects of a new infant formula on the changes in the newborn body composition over time: weight gain, anthropometric data, incidence of infections, digestive tolerance (flatulence, vomiting and regurgitation), feces (consistency and frequency), behavior (restlessness, colic, nocturnal awakenings), count of probiotic strains of the intestinal microbiota in feces, safety and tolerability of the investigational products (measured as number, frequency and severity of adverse events in all branches of the study)